Fineline Cube

Follow:
14687 Articles
BMS's RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs
CompanyDrug

BMS’s RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs

Huadong Medicine Subsidiary Doer Bio's DR30206 Cleared for Clinical Trials by NMPA – Triple‑Targeting PD‑L1/VEGF/TGF‑β Fusion Protein Advances Against Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CompanyDrug

Huadong Medicine Subsidiary Doer Bio’s DR30206 Cleared for Clinical Trials by NMPA – Triple‑Targeting PD‑L1/VEGF/TGF‑β Fusion Protein Advances Against Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Shanghai Ark Biopharmaceutical's AK0406 Receives FDA IND Clearance for Phase 2 Trial – Long‑Acting Antiviral‑Fc Conjugate Advances Toward Influenza Prevention
CompanyDrug

Shanghai Ark Biopharmaceutical’s AK0406 Receives FDA IND Clearance for Phase 2 Trial – Long‑Acting Antiviral‑Fc Conjugate Advances Toward Influenza Prevention

T-MAXIMUM's MT027 Wins FDA Clearance for Phase 2 Study – Non‑Viral Allogeneic B7‑H3 CAR‑T Targets Advanced Solid Tumor Brain Metastases
CompanyDrug

T-MAXIMUM’s MT027 Wins FDA Clearance for Phase 2 Study – Non‑Viral Allogeneic B7‑H3 CAR‑T Targets Advanced Solid Tumor Brain Metastases

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease
Policy / Regulatory

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot
CompanyDrug

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease
CompanyDrug

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled
CompanyDrug

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus
CompanyDrug

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise
CompanyDrug

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise